Light Chain Bioscience AG, a Swiss biotech company, agreed to purchase all shares in NovImmune SA, a company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune related disorders and cancer. Patinex and BZ Bank are the selling majority shareholders of NovImmune.

Bär & Karrer acted as legal advisor to Patinex and BZ Bank. The team included Ralph Malacrida, Faton Aliu, Tim Salz, Janine Wüst and Aranya Di Francesco (all M&A and Financing), Susanne Schreiber, Markus Mühlemann, David Weimann, Alexander Weisser and Caroline Ruggli (Tax).